



Key Patent Application Accepted in India, China, Australia and the European Union

LAVAL, QC, October 22 -- Chlorion Pharma Inc. announced today that it has received several notifications of acceptance for the PCT patent application “CNS chloride modulation and uses thereof”, licensed exclusively from Université Laval in Quebec City.

Specifically, Chlorion and Université Laval were jointly notified of the admissibility of the patent application by patent authorities in China, India, Australia and the European Union.

Dr. Jeffrey Coull, President & CEO of Chlorion, stressed the importance of the successful patent applications: “Particularly in the case of India and China, there is a very large population of patients suffering chronic pain. Patent coverage of key elements of our novel therapeutic strategy in these countries certainly adds to the market potential for the products our company is developing.”

It is anticipated that the patents will officially issue in the said regions in the coming months. The company also expects a similarly positive response from other patent agencies shortly, including in the United States, Japan, and Canada.

Two other PCT patent application families submitted by Université Laval and licensed exclusively to Chlorion continue to be reviewed in the divisional phase.

About the Company

Chlorion Pharma Inc. is a biopharmaceutical company focused on neurotherapeutics that act via the modulation of chloride in the central nervous system. Presently, the company is developing first-in-class therapeutics for the treatment of neuropathic pain and epilepsy.

For more information, please visit our website at www.chlorion.com.

##